SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

Autologous, CAR-T, CD19

March 12, 2021

Thoughts on Kymriah's Approval in Singapore; Could Singapore Become a Hub for Cell Therapy Medical Tourism in Southeast Asia?

Here is a brief preview of this blast: On Tuesday, March 9, Novartis received approval (press release, PR Newswire, Mar 2021) for Kymriah (CD19 CAR-T) in pediatric r/r ALL and adult r/r DLBCL by Singapore’s Health Sciences Authority (HSA). Of note, Kymriah is now the first commercially approved CAR-T therapy in the region. Below, Celltelligence provides insights on how Novartis could leverage Kymriah’s approval in Singapore to expand within the Asia-Pacific market, Singapore's pivot towards cell therapy manufacturing, and how BMS and Gilead compare in the region.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.